Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Investigators at University of Cologne, Medical Department zero in on vaccines
October 15th, 2008
According to a study from Cologne, Germany, "Cellular adjuvants have recently been studied as tools to induce immune responses and thus to control malignancies. They are, therefore, subject to intensive research in the field of tumor immunotherapy and immunology." "In particular, dendritic cells have been shown to efficiently present antigens to T cells and, thus, induce primary and secondary immune responses. Nevertheless, dendritic cell-based clinical applications are challenged by their low frequency, inability to grow in culture and, also, lack of purity. Among other alternatives, CD40-activated B cells have previously been shown to efficiently present antigens and...
Source: Vaccine Weekly (2008-10-15)
|
